首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

1618135

腫瘤精準醫學市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Oncology Precision Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月30日 | 出版商:

Global Market Insights Inc. | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球腫瘤精準醫療市場規模達到417億美元，預計2024年至2032年複合年成長率為9.1%。隨著癌症診斷數量的增加，對特定基因突變的個人化治療方案的需求不斷增加，最終提高治療效果。這一趨勢凸顯了精準腫瘤治療的必要性，這種治療能夠提供有針對性的、有效的治療，且副作用最小，從而改善患者的生活品質。此外，由於對癌症基因組學的更深入了解以及下一代定序（NGS）和液體活體組織切片等尖端技術的引入，市場正在迅速發展。

這些創新有助於識別特定的基因突變和生物標記物，幫助腫瘤學家為個別患者選擇最合適的標靶療法或免疫療法。就癌症類型而言，市場涵蓋多種類別，包括乳癌、肺癌、血液癌、胃腸道癌、皮膚癌等。 2023 年，乳癌細分市場以 22.3% 的佔有率引領市場，因為精準醫療專注於與此類癌症相關的特定基因突變的標靶治療。透過強調分子分析和客製化治療計劃，該細分市場在市場上獲得了巨大的吸引力。

在考慮給藥途徑時，腫瘤精準醫療市場分為口服、靜脈注射和其他給藥方式。 2023 年，僅口腔領域的價值就達到 268 億美元，預計在預測期內複合年成長率為 10.2%。這種成長可歸因於人們越來越傾向於口服藥物，與靜脈注射藥物相比，口服藥物提供了更大的便利性。精準醫學中標靶治療的興起也推動了口服藥物領域的發展，因為包括激酶抑制劑在內的許多腫瘤藥物都被製成口服藥物。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	417 億美元
預測值	907 億美元
複合年成長率	9.1%

這使得能夠根據個體腫瘤的獨特基因組成更精確地靶向癌細胞。北美腫瘤精準醫療市場將於 2023 年達到 213 億美元，預計 2024 年至 2032 年複合年成長率為 10.2%。研究與開發。公部門和私部門對癌症研究的投資刺激了創新，而監管機構則加快了精準治療的核准流程。醫療保健提供者和患者對個人化醫療的認知不斷提高，進一步提高了採用率，推動了市場擴張。

產業生態系統分析
產業影響力
- 成長動力
  - 癌症盛行率上升
  - 提高認知並轉向個人化治療
  - 技術進步
- 產業陷阱與挑戰
  - 精準醫療成本高
  - 複雜的法規核准流程
成長潛力分析
監管環境
未來市場趨勢
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按癌症類型，2021 - 2032 年

主要趨勢
乳癌
肺癌
血液/血液癌症
胃腸癌
皮膚癌
膀胱癌
頭頸鱗狀細胞癌
子宮頸癌
其他癌症類型

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

主要趨勢
口服
靜脈
其他給藥途徑

第 7 章：市場估計與預測：按分子類型，2021 - 2032

主要趨勢
小分子
生物製劑

第 8 章：市場估計與預測：按藥物類別，2021 - 2032 年

主要趨勢
激酶抑制劑
免疫檢查點抑制劑
酵素抑制劑
其他藥物類別

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第 10 章：公司簡介

AbbVie
AstraZeneca
Bayer
Blueprint Medicines Corporation
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Novartis
Organon
Pfizer

簡介目錄

Product Code: 11876

The Global Oncology Precision Medicine Market reached USD 41.7 billion in 2023 and is projected to expand at a CAGR of 9.1% from 2024 to 2032. A key factor driving the growth of this market is the rising incidence of cancer. With an increasing number of cancer diagnoses, there is a heightened demand for personalized treatment options that target specific genetic mutations, ultimately enhancing treatment outcomes. This trend highlights the necessity for precision oncology therapies that provide targeted, effective treatments with minimal side effects, thus improving patients' quality of life. Moreover, the market is rapidly advancing due to a greater understanding of cancer genomics and the introduction of cutting-edge technologies like next-generation sequencing (NGS) and liquid biopsy.

These innovations facilitate the identification of specific genetic mutations and biomarkers, helping oncologists select the most suitable targeted therapies or immunotherapies for individual patients. In terms of cancer types, the market encompasses various categories, including breast cancer, lung cancer, hematologic cancers, gastrointestinal cancers, skin cancer, and several others. The breast cancer segment led the market with a 22.3% share in 2023, as precision medicine focuses on targeted therapies addressing specific genetic mutations associated with this type of cancer. By emphasizing molecular profiling and customized treatment plans, this segment has gained significant traction in the market.

When considering routes of administration, the oncology precision medicine market is divided into oral, intravenous, and other delivery methods. The oral segment alone was valued at USD 26.8 billion in 2023 and is expected to grow at a CAGR of 10.2% during the forecast period. This growth can be attributed to the growing inclination for oral medicines, which offer greater convenience compared to intravenous options. The rise of targeted therapies in precision medicine has also bolstered the oral segment, as many oncology drugs, including kinase inhibitors, are formulated as oral medications.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$41.7 Billion
Forecast Value	$90.7 Billion
CAGR	9.1%

This allows for more precise targeting of cancer cells based on the unique genetic makeup of individual tumors. North America oncology precision medicine market reached USD 21.3 billion in 2023 and is forecasted to grow at a CAGR of 10.2% from 2024 to 2032. The growth in this region is primarily fueled by a high prevalence of cancer and a robust healthcare infrastructure that supports innovative research and development. Investments from both the public and private sectors in cancer research stimulate innovation, while regulatory bodies expedite the approval process for precision therapies. Increased awareness of personalized medicine among healthcare providers and patients further enhances adoption rates, driving market expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of cancer
  - 3.2.1.2 Increasing awareness and shift towards personalized therapies
  - 3.2.1.3 Technological advancements
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of precision medicine
  - 3.2.2.2 Complex regulatory approval process
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Breast cancer
5.3 Lung cancer
5.4 Blood/ hematologic cancer
5.5 Gastrointestinal cancer
5.6 Skin cancer
5.7 Bladder cancer
5.8 Head & neck squamous cell cancer
5.9 Cervical cancer
5.10 Other cancer types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Intravenous
6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Molecule Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Small molecules
7.3 Biologics

Chapter 8 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Kinase inhibitors
8.3 Immune checkpoints inhibitors
8.4 Enzyme inhibitors
8.5 Other drug classes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE